AI-generated summary
This study protocol describes a planned randomised controlled trial of red light therapy in 158 adults with pathologic myopia, with the intervention group receiving 660 nm light-emitting diode treatment and the control group a sham treatment over 12 months. The authors have not yet reported results; the primary outcome is the change in choroidal vascular density and vessel volume index at 12 months, and the trial's safety and efficacy in slowing fundus atrophic lesions are to be evaluated.
- Participants
- 158
- Who or what was studied
- Adults aged 18 to 55 years with pathologic myopia
- Wavelengths
- 660 nm
- Limits stated in the abstract
- This is a study protocol, so no outcomes or efficacy findings are reported yet.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on bmjopen.bmj.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 660 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Myopia, Light-emitting diode, Repeated low-level red light, Control group, Trial registration, Primary outcome, Wavelength, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.